이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

만성 궤양 치료에서 ZKARE® 겔 및 부속품 ZKAPI®의 효능과 안전성: 전향적, 무작위, 대조 임상 연구.

2026년 11월 2일 업데이트: i+Med S.Coop.

만성 궤양 치료에서 ZKARE® 겔 및 그 보조제 ZKAPI®의 효능과 안전성: 전향적, 무작위, 대조 임상 연구

This prospective, randomized, single-blind, controlled clinical investigation evaluates the efficacy and safety of ZKARE®, a topical polymeric gel dressing, and its accessory applicator ZKAPI®, for the treatment of chronic, hard-to-heal ulcers. The study includes 134 ulcers of different etiologies-pressure ulcers, neuropathic diabetic foot ulcers, and venous leg ulcers-meeting predefined selection criteria. Participants are randomized to receive either ZKARE® in addition to standard wound care or standard care alone.

The primary efficacy endpoint is the change in wound condition assessed through the RESVECH 2.0 scale, recorded at baseline and throughout treatment and follow-up visits. The primary safety endpoint is the incidence of serious adverse events (SAEs). Secondary outcomes include percentage and rate of wound closure, total closure rate, estimated time to full closure, quality-of-life measures (DLQI), patient satisfaction, investigator global assessment, cost-effectiveness, and product usability. The study aims to generate evidence on the performance, safety, and clinical usefulness of ZKARE® for chronic wound management.

연구 개요

상세 설명

Chronic ulcers such as pressure ulcers, neuropathic diabetic foot ulcers and venous leg ulcers frequently fail to follow normal healing phases and require comprehensive management. Many existing dressings act through a single mechanism and are limited in effectiveness for complex or exudative wounds. ZKARE® is a sterile, biocompatible polymeric gel intended for topical use that provides a moist microenvironment, absorbs excess exudate and contributes to bacterial control. The product is applied using ZKAPI®, a sterile Luer-Lock applicator designed to improve precision and ease of administration.

This prospective, randomized, single-blind, controlled clinical investigation compares ZKARE® plus standard care with standard care alone in 134 chronic ulcers of different etiologies. Patients may contribute more than one ulcer if lesions are independent. After informed consent, ulcers are randomized, and treatment sessions follow routine clinical practice, with ZKARE® added only in the investigational arm. Blinding is maintained by preventing direct visualization of the wound and through iso-appearance of materials. Follow-up visits occur at approximately 2, 4, 8 and 12 weeks.

The primary efficacy endpoint is the change in RESVECH 2.0 score, recorded at baseline, each treatment session and all follow-up visits; a ≥2-point improvement at Week 4 is considered clinically relevant. The primary safety endpoint is the incidence of serious adverse events. Secondary outcomes include percentage and rate of wound closure, total closure rate, estimated time to full closure, DLQI, patient satisfaction, investigator global assessment, usability and cost-effectiveness, as well as non-serious adverse events.

Group comparisons use appropriate statistical tests for categorical and continuous variables, repeated-measures analyses and ANCOVA where applicable, under an intention-to-treat approach. The sample size of 134 ulcers gives 80% power to detect expected differences in RESVECH 2.0 change. The study aims to evaluate the clinical performance and safety of ZKARE® and ZKAPI® in the treatment of chronic hard-to-heal ulcers

연구 유형

중재적

등록 (추정된)

134

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adult patients (≥18 years).
  • Presence of at least one chronic hard-to-heal ulcer, including any of the following etiologies: Grade II, III or IV pressure ulcers; neuropathic diabetic foot ulcers (grade I, II or III), Wagner Grade I-III or Texas 0, I, II, III / Stage B; class C6/C6r venous leg ulcers measured with CEAP scale ; neuro-ischaemic ulcers with adequate distal perfusion (ABI/ITB ≥ 0.7-0.89; mild PAD); mixed-etiology venous ulcers and any chronic lower-limb lesion with palpable distal pulses.
  • Ulcer size between 1 cm² and 100 cm².
  • Ability and willingness to comply with all study visits and procedures according to the clinical protocol.
  • Ability to understand and sign the informed consent, obtained before performing any protocol-specific procedures.

Exclusion Criteria:

  • Ulcers of etiologies not listed in the inclusion criteria.
  • Ischaemic, neoplastic or atypical ulcers.
  • Severe comorbidities judged to compromise safety or study compliance, including: severe malnutrition, palliative/terminal status, severe anemia, decompensated heart failure, chronic kidney disease stage III/IV or in dialysis.
  • Ulcers with moderate-severe or severe infection per PEDIS-IDSA infection grading scale.
  • Known allergy or sensitivity to any component of the investigational product.
  • Any condition that, in the investigator's opinion, may compromise patient safety or adherence to the protocol.
  • Pregnancy or planned breastfeeding.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: ZKARE®

Participants assigned to this arm receive standard wound care plus topical application of the investigational gel ZKARE®, applied using the ZKAPI® applicator during each wound-care session.

ZKARE® is applied topically after routine wound cleansing and debridement. Using the sterile ZKAPI® applicator, the gel is distributed to fully cover the wound bed, including irregular or cavitated areas. The treated wound is then covered with the appropriate secondary dressing following standard clinical practice. The application is repeated at each treatment session until complete closure or the end of the 12-week follow-up period. All sessions include RESVECH 2.0 scoring, standardized photographs, and safety assessments

활성 비교기: Standard Wound Care

Participants assigned to this arm receive standard wound management according to routine clinical practice, without the use of the investigational product.

Standard care includes wound cleansing, debridement when required, and selection of secondary dressings according to wound characteristics such as exudate level, infection status, depth, and perilesional skin condition. No investigational gel is applied. At each treatment visit and follow-up time point, standardized wound photographs, RESVECH 2.0 scoring, closure metrics, and safety assessments are recorded according to the same schedule as the investigational arm.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
RESVECH Scale 2.0
기간: 12 weeks or wound healing

Change in the RESVECH 2.0 wound assessment scale, which evaluates wound size, depth, granulation tissue quality, exudate amount/type, clinical signs of infection/inflammation, and perilesional skin condition.

Measured at baseline and at each treatment and follow-up visit until complete closure or at week 12. A ≥2-point improvement at week 4 is considered clinically relevant.

12 weeks or wound healing
Incidence of Serious Adverse Events (SAEs)
기간: 12 weeks

Incidence, frequency, and nature of serious adverse events during the study.

12 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Wound Closure Rate (mm²/day)
기간: 12 weeks

Rate of epithelialization based on the area healed divided by the time since treatment initiation.

Assessed at each treatment and follow-up visit.

12 weeks
Percentage of Wound Closure (%)
기간: 12 weeks

Percentage reduction of the initial wound area at each assessment. A ≥30% reduction by week 4 is considered clinically relevant.

Kaplan-Meier curves may be used to evaluate closure thresholds (≥30%-90%).

12 weeks
Total Wound Closure (%)
기간: 12 weeks

Percentage of wounds achieving complete epithelialization.

12 weeks
Estimated Time to Full Closure (days)
기간: 12 weeks

For wounds not completely healed by week 12, linear regression based on closure rate is used to estimate time to complete healing.

12 weeks
Cost-Effectiveness Analysis (Healthcare Resources Used)
기간: 12 weeks

Quantification of materials, products, consumables, and healthcare professional time in each treatment session.

Reported as €/patient.

12 weeks
Dermatology Life Quality Index (DLQI) Score
기간: 12 weeks

Change in DLQI score (0-30), with higher scores indicating worse dermatology-related quality of life.

12 weeks
Patient Satisfaction (Likert Scale)
기간: 12 weeks

Patient satisfaction rated at study end (Very dissatisfied, dissatisfied, neutral, satisfied and very satisfied).

Outcome to be reported as the percentage of "Satisfied" + "Very satisfied" answers.

12 weeks
Investigator Global Assessment (IGA)
기간: 12 weeks

Clinical impression of overall wound evolution (Worsening / No improvement / Mild improvement / Significant improvement).

Outcome to be reported as the percentage of mild or significant improvement achievement.

12 weeks
Incidence of Non-Serious Adverse Events (AEs)
기간: 12 weeks

Recording of the incidence and nature of all non-serious adverse events.

12 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 11월 14일

기본 완료 (추정된)

2027년 3월 1일

연구 완료 (추정된)

2027년 8월 1일

연구 등록 날짜

최초 제출

2026년 2월 5일

QC 기준을 충족하는 최초 제출

2026년 2월 5일

처음 게시됨 (실제)

2026년 2월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 2월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다